Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.69 |
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160333 | 0.94 | ADORA2A (0.67) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5161127 | 0.82 | ADORA2A (0.85) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL7209277 | 0.82 | ADORA2A (0.80) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5161160 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5160841 | 0.81 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5163571 | 0.81 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5160311 | 0.80 | ADORA2A (0.51) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL1285904 | 0.80 | ADORA3 (0.51) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5161260 | 0.80 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 | |
| SCHEMBL5162113 | 0.80 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BTMIGD3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885ADORA2A 1/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.